Diagnostic value of telomerase activity in gynecologic malignancies

被引:0
|
作者
Nagai, N
Murakami, J
Oshita, T
Ohama, K
Tahara, H
机构
[1] Hiroshima Univ, Sch Med, Dept Obstet & Gynecol, Minami Ku, Hiroshima 7348551, Japan
[2] Hiroshima Univ, Sch Med, Dept Cellular & Mol Biol, Minami Ku, Hiroshima 7348551, Japan
关键词
gynecologic malignancies; semiquantification; telomerase; TRAP assay;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We investigated the diagnostic significance of telomerase activity in gynecological malignancies. Tissue samples were obtained from 24 cervical cancers, 27 uterine cancers (22 endometrial cancers and five sarcomas), 33 ovarian cancers (31 epithelial tumors and 2 germ cell tumors), and 11 benign ovarian tumors. In addition, cervical cytology specimens were obtained from 30 squamous intraepithelial lesions (13 low grade and 17 high grade), and from 22 normal females. Telomerase activity was detected using the TRAP assay, and the relative telomerase activity was obtained using the BioMax DNA image analysis system. Telomerase activity was detected in 22/24 (91.7%) cervical cancers, 23/27 (85.2%) uterine tumors and 30/33 (90.9%) ovarian cancers. Weak telomerase activity was detected in two mature cystic teratomas and also found in 9/17 (52.9%) high grade SIL and 2/13 (15.4%) low grade lesions. Telomerase activity showed no relationship with tumor histology or clinical stage, and there was no statistically significant difference between patients with uterine cancer and ovarian cancer. Relative telomerase activity showed a correlation with the dilution assay, and significantly higher telomerase activity was found in uterine cervical cancer compared with precancerous lesions and in ovarian cancer compared with benign ovarian tumors. After establishment of an assay for telomerase, it may be useful for cancer diagnosis and identification of high-risk groups.
引用
收藏
页码:481 / 488
页数:8
相关论文
共 50 条
  • [41] LYMPHOSCINTIGRAPHY IN GYNECOLOGIC MALIGNANCIES
    BLOOMER, WD
    SEMINARS IN NUCLEAR MEDICINE, 1983, 13 (01) : 54 - 60
  • [42] IMRT in gynecologic malignancies
    Roeske, J
    MEDICAL PHYSICS, 2005, 32 (06) : 2145 - 2145
  • [43] Vitamins in Gynecologic Malignancies
    Wierzbowska, Natalia
    Olszowski, Tomasz
    Chlubek, Dariusz
    Kozlowski, Mateusz
    Cymbaluk-Ploska, Aneta
    NUTRIENTS, 2024, 16 (09)
  • [44] Gynecologic malignancies - Introduction
    Randall, Marcus E.
    SEMINARS IN RADIATION ONCOLOGY, 2006, 16 (03) : 137 - 137
  • [45] Staging of gynecologic malignancies
    Odicino, F
    Favalli, G
    Zigliani, L
    Pecorelli, S
    SURGICAL CLINICS OF NORTH AMERICA, 2001, 81 (04) : 753 - +
  • [46] RARE GYNECOLOGIC MALIGNANCIES
    SCHINK, JC
    LURAIN, JR
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 1991, 3 (01) : 78 - 90
  • [47] Value of diffusion weighted MRI for pelvic nodal staging in patients with gynecologic malignancies
    Viala-Trentini, Muriel
    Faget, Claire
    Rouanet, Jean-Pierre
    IMAGERIE DE LA FEMME, 2014, 24 (02) : 62 - 67
  • [48] Advantages of assaying telomerase activity in ascites for diagnosis of digestive tract malignancies
    Li, Chung-Pin
    Huang, Tze-Sing
    Chao, Yee
    Chang, Full-Young
    Whang-Peng, Jacquline
    Lee, Shou-Dong
    WORLD JOURNAL OF GASTROENTEROLOGY, 2004, 10 (17) : 2468 - 2471
  • [49] Telomerase activity and telomere length in pediatric patients with malignancies undergoing chemotherapy
    M Engelhardt
    MF Ozkaynak
    P Drullinsky
    C Sandoval
    O Tugal
    S Jayabose
    MAS Moore
    Leukemia, 1998, 12 : 13 - 24
  • [50] Diagnostic Value of the Survivin Autoantibody in Four Types of Malignancies
    Xiu, Yuting
    Sun, Baosheng
    Jiang, Yongli
    Wang, Aifu
    Liu, Linlin
    Liu, Ying
    Sun, Shilong
    Huangfu, Mingmei
    GENETIC TESTING AND MOLECULAR BIOMARKERS, 2018, 22 (06) : 384 - 389